Search results for "Vaccine"

showing 10 items of 801 documents

Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic…

1996

Abstract Antibodies directed to the HBs antigen indicate viral clearance and the development of life-long immunity in patients that recovered from HBV infection. In HBs antigen vaccine recipients anti-HBs antibodies provide protective immunity. However, little is known about the regulation of this HBs-specific antibody response. The existence of anti-HBs-secreting B cells was demonstrated using the highly sensitive ELISPOT technique compared with conventional ELISA in serum and cell culture supernatants. In the peripheral blood of patients with acute self-limited hepatitis B, HBs-specific B cells were demonstrated with a high frequency despite undetectable anti-HBs serum antibodies. HBV-imm…

AdultMaleAdolescentT-LymphocytesImmunologymedicine.disease_cause03 medical and health sciences0302 clinical medicineImmune systemNeutralization TestsImmunityHumansImmunology and AllergyMedicineHepatitis B VaccinesHepatitis B AntibodiesRapid PublicationsB cellAgedHepatitis Chronic030304 developmental biologyHepatitis B virusB-LymphocytesImmunity Cellular0303 health sciencesHepatitis B Surface Antigensbiologybusiness.industryELISPOTvirus diseasesMiddle AgedHepatitis BHepatitis Bmedicine.diseasebiology.organism_classificationVirologydigestive system diseases3. Good healthmedicine.anatomical_structureHepadnaviridaeAcute DiseaseImmunologybiology.proteinFemale030211 gastroenterology & hepatologyAntibodybusinessClinical and Experimental Immunology
researchProduct

The clinical value of PSA increase during intravesical adjuvant therapy for nonmuscle-invasive bladder cancer.

2016

Introduction Prostatic Specific Antigen (PSA), Bacillus Calmette-Guerin (BCG) increase after intravesical BCG has been reported. The need of prostate biopsy in these patients is object of debate. The aim of our study was to evaluate the effect of intravesical therapy on PSA after transurethral resection (TUR) of nonmuscle-invasive bladder cancer (NMIBC). Materials and methods Patients undergoing intravesical chemotherapy or immunotherapy for NMIBC were entered. PSA was measured before TUR, before the first and after the sixth instillation, 30 and 90 days after the last instillation. Patients with PSA ≥4 ng/ml or palpable prostate nodule were excluded. Results Out of 130 patients, 105 were e…

Adultmedicine.medical_specialtyProstate biopsymedicine.medical_treatment030232 urology & nephrologyUrologyAntineoplastic Agents03 medical and health sciencesProstate cancer0302 clinical medicineAdjuvants ImmunologicBiopsyIntravesical instillation Prostate cancer PSAmedicineAdjuvant therapyCombined Modality TherapyHumansNeoplasm InvasivenessAgedAged 80 and overChemotherapyBladder cancermedicine.diagnostic_testbusiness.industryGeneral MedicineImmunotherapyMiddle AgedProstate-Specific Antigenmedicine.diseaseCombined Modality TherapyAdministration IntravesicalUrinary Bladder Neoplasms030220 oncology & carcinogenesisBCG VaccinebusinessUrologia
researchProduct

International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georg…

2009

An international meeting on Bordetella pertussis assay standardization and harmonization was held at the Centers for Disease Control and Prevention (CDC), Atlanta, GA, 19-20 July 2007. The goal of the meeting was to harmonize the immunoassays used for pertussis diagnostics and vaccine evaluation, as agreed upon by academic and government researchers, regulatory authorities, vaccine manufacturers, and the World Health Organization (WHO). The primary objectives were (1) to provide epidemiologic, laboratory, and statistical background for support of global harmonization; (2) to overview the current status of global epidemiology, pathogenesis and immunology of pertussis; (3) to develop a consen…

Settore MED/07 - Microbiologia E Microbiologia ClinicaBordetella pertussisStandardizationVaccine evaluationU.S.HarmonizationMedical and Health SciencesArticleBordetella pertussisPertussis vaccinesVirologyHumansMedicineCenters for Disease Control and PreventionWhooping coughLicensureGovernmentMedical educationWhooping coughAgricultural and Veterinary SciencesGeneral VeterinaryGeneral Immunology and MicrobiologybiologyClinical Laboratory Techniquesbusiness.industryPublic Health Environmental and Occupational HealthStandardization of serologic assaysBiological Sciencesbiology.organism_classificationmedicine.diseaseUnited StatesAtlantaInfectious DiseasesImmunologyBordetella pertussis Whooping cough Standardization of serologic assays ELISA Pertussis vaccinesMolecular MedicineELISAbusinessVaccine
researchProduct

The Italian Version of the Adult Vaccine Hesitancy Scale (aVHS) for the Working-Age Population: Cross-Cultural Adaptation, Reliability, and Validity

2022

The adult Vaccine Hesitancy Scale (aVHS) is valid and reliable for evaluating attitudes toward vaccine preventable diseases (VPDs). The aim of the present study was to evaluate the cross-cultural adaptation, reliability, and validity of the Italian version of the aVHS. After cross-cultural adaptation of the aVHS, internal consistency (IC), intra-class correlation (ICC), and content validity (S-CVI) were evaluated through a survey on 160 workers. Results of the ICC were analyzed on questionnaires administered twice at a distance of two months and revealed a satisfactory reproducibility (0.87). The IC of the aVHS was assessed by the Cronbach alpha coefficient test, with a result of 0.94, demo…

Vaccine preventable diseasePharmacologySARS-CoV-2VaccinationImmunologyCOVID-19vaccination; workplace; SARS-CoV-2; vaccine hesitancy; Italy; worker; COVID-19; vaccine preventable diseaseSARS‐CoV‐2Infectious DiseasesItalyCOVID‐19Drug DiscoveryWorkerPharmacology (medical)WorkplaceVaccine hesitancyVaccines
researchProduct

Adult congenital heart disease: Special considerations for COVID-19 and vaccine allocation/prioritization

2021

Abstract Individuals with the highest risk for adverse outcomes of COVID-19 should be prioritized by the vaccine allocation policies. We have conducted a literature review of published studies, which comprehend congenital heart disease (CHD) and COVID-19, in order to present the overall evidences of both exposure and clinical risk of patients with adult congenital heart disease (ACHD) and to propose a risk profile schema for those patients to be incorporated into vaccine distribution decisions.

Prioritizationmedicine.medical_specialtyHeart diseaseCoronavirus disease 2019 (COVID-19)business.industryAdverse outcomesCOVID-19medicine.diseaseRisk profileArticleRisk factorsSchema (psychology)RC666-701ACHDMedicineDiseases of the circulatory (Cardiovascular) systembusinessIntensive care medicineClinical risk factorVaccine
researchProduct

Q fever in Europe: current aspects of aetiology, epidemiology, human infection, diagnosis and therapy.

1987

Il s'agit d'une zoonose. Elle est en general asymptomatique bien que des decouvertes nouvelles aussi bien chez l'homme que chez l'animal mettent en evidence des syndromes cliniques associes en particulier des maladies chroniques graves

Microbiology (medical)Gynecologymedicine.medical_specialtyPathologybusiness.industryQ feverGeneral MedicineInfection diagnosismedicine.diseaseEuropeInfectious DiseasesCoxiellaGeneral practiceEpidemiologyAcute DiseaseBacterial VaccinesChronic DiseasemedicineEtiologyAnimalsHumansbusinessQ FeverInfection
researchProduct

Pneumococcal conjugate vaccine for acute otitis media—yes or no?

2003

Vaccines ConjugateAcute otitis mediabusiness.industryInfantGeneral MedicinePneumococcal conjugate vaccinePneumococcal VaccinesOtitis MediaChild PreschoolAcute DiseaseImmunologymedicineHumansChildbusinessmedicine.drugThe Lancet
researchProduct

Comparative Antitumor Effect of Preventive versus Therapeutic Vaccines Employing B16 Melanoma Cells Genetically Modified to Express GM-CSF and B7.2 i…

2012

Cancer vaccines have always been a subject of gene therapy research. One of the most successful approaches has been working with genetically modified tumor cells. In this study, we describe our approach to achieving an immune response against a murine melanoma model, employing B16 tumor cells expressing GM-CSF and B7.2. Wild B16 cells were injected in C57BL6 mice to cause the tumor. Irradiated B16 cells transfected with GM-CSF, B7.2, or both, were processed as a preventive and therapeutic vaccination. Tumor volumes were measured and survival curves were obtained. Blood samples were taken from mice, and IgGs of each treatment group were also measured. The regulatory T cells (Treg) o…

Cytotoxicity Immunologicnon-viralHealth Toxicology and MutagenesisGenetic enhancementMelanoma Experimentallcsh:MedicineToxicologyTransfectionT-Lymphocytes RegulatoryImmunoglobulin GArticleMiceImmune systemCell Line TumormedicineAnimalsbiologylcsh:RGene Transfer TechniquesCancerGranulocyte-Macrophage Colony-Stimulating FactorGM-CSFTransfectionGenetic Therapymedicine.diseaseSurvival Analysisgene therapyGenetically modified organismVaccinationMice Inbred C57BLGranulocyte macrophage colony-stimulating factorB7.2Immunoglobulin GImmunologybiology.proteinB7-2 AntigenNeoplasm Transplantationcancer vaccinesmedicine.drugToxins
researchProduct

Synthetic Antitumor Vaccines from Tetanus Toxoid Conjugates of MUC1 Glycopeptides with the Thomsen-Friedenreich Antigen and a Fluorine-Substituted An…

2010

Breast NeoplasmsCancer VaccinesAntibodiesCatalysisMiceCell Line TumorTetanus ToxoidmedicineAnimalsHumansAntigens Tumor-Associated CarbohydrateMUC1Vaccines SyntheticThomsen-Friedenreich AntigenChemistryTetanusMucin-1GlycopeptidesToxoidFluorineGeneral ChemistryFlow Cytometrymedicine.diseaseGlycopeptideBiochemistryFemaleConjugateAngewandte Chemie International Edition
researchProduct

Italian association for the study of the liver position statement on SARS-CoV2 vaccination.

2021

The vaccination campaign against Sars-CoV-2 commenced in Italy at the end of December 2020. The first ones to receive the immunization against the virus were the health workers and the residents of nursing homes, following which the vaccine would be available for the entire population, beginning with the most vulnerable individuals. SARS-CoV2 vaccines have been demonstrated to be safe for the general population, although no data for patients with liver diseases or those having undergone liver transplantation are available so far. The present position statement AISF is an attempt to suggest, based on the published data on the impact of Sars-Cov-2 infection in patients with chronic liver dise…

medicine.medical_specialtyCOVID-19 VaccinesSars-CoV-2medicine.medical_treatmentPopulationLiver transplantationChronic liver diseaseRisk AssessmentPatient safetyEpidemiologyMedicineChronic liver disease Sars-CoV-2 Vaccination Humans Immunosuppressive Agents Italy Liver Transplantation Patient Safety Patient Selection Risk Adjustment Risk Assessment SARS-CoV-2 Transplant Recipients Treatment Outcome COVID-19 COVID-19 Vaccines Immunization Programs Liver DiseasesHumanseducationeducation.field_of_studyHepatologybusiness.industryImmunization ProgramsLiver DiseasesPatient SelectionChronic liver disease; Sars-CoV-2; VaccinationVaccinationChronic liver diseaseGastroenterologyCOVID-19medicine.diseaseTransplant RecipientsLiver TransplantationVaccinationTreatment OutcomeImmunizationItalyFamily medicineChronic liver disease; Sars-CoV-2; Vaccination; Humans; Immunosuppressive Agents; Italy; Liver Transplantation; Patient Safety; Patient Selection; Risk Adjustment; Risk Assessment; SARS-CoV-2; Transplant Recipients; Treatment Outcome; COVID-19; COVID-19 Vaccines; Immunization Programs; Liver DiseasesRisk AdjustmentPatient SafetyPosition PaperbusinessRisk assessmentImmunosuppressive AgentsDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct